Latest Period
Q4 2025
Security Snapshot
Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) Institutional Ownership
CUSIP: 140755307
13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026
Institutions Reporting
64
Shares (Excl. Options)
2,824,911
Price
$4.30
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- TVRD on Nasdaq
- Shares outstanding
- 9,470,889
- Price per share
- $3.18
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 2,824,911
- Total reported value
- $12,111,919
- % of total 13F portfolios
- 0%
- Share change
- +220,972
- Value change
- -$18,315,547
- Number of holders
- 64
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 140755307.
- 64 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 64 to 11 between Q4 2025 and Q1 2026.
- Reported value moved from $12,111,919 to $4,019.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 64 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 140755307?
CUSIP 140755307 identifies TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 140755307:
Significant Owners of Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Slate Path Capital LP | 7.5% | $19,257,627 | 704,118 | Slate Path Capital LP | 30 Jun 2025 | |||
| DePinho Ronald A | 4.5% | $1,939,164 | 426,190 | Ronald A. DePinho | 31 Dec 2025 | |||
| Vifor (International) Ltd | 2.2% | $4,725,695 | 205,465 | Vifor (International) Ltd. | 15 Apr 2025 |
As of 31 Dec 2025, 64 institutional investors reported holding 2,824,911 shares of Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD). This represents 30% of the company’s total 9,470,889 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) together control 29% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Slate Path Capital LP | 7.4% | 704,118 | 0% | 0.04% | $3,027,707 |
| VANGUARD GROUP INC | 4.5% | 424,821 | +1.3% | 0% | $1,826,730 |
| BlackRock, Inc. | 4.1% | 391,000 | +19% | 0% | $1,681,300 |
| AMERICAN FINANCIAL GROUP INC | 2.4% | 223,659 | 0.35% | $961,734 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 157,133 | +6.2% | 0% | $675,826 |
| STATE STREET CORP | 1.2% | 115,501 | +84% | 0% | $496,654 |
| RENAISSANCE TECHNOLOGIES LLC | 1.1% | 104,500 | +246% | 0% | $449,350 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 1.1% | 101,034 | +352% | 0% | $434,446 |
| MORGAN STANLEY | 0.89% | 84,466 | +2131% | 0% | $363,205 |
| Duncan Williams Asset Management, LLC | 0.85% | 80,771 | 0.08% | $311,776 | |
| Squarepoint Ops LLC | 0.55% | 51,783 | +534% | 0% | $222,667 |
| NORTHERN TRUST CORP | 0.51% | 47,882 | +13% | 0% | $205,893 |
| JANE STREET GROUP, LLC | 0.5% | 47,444 | 0% | $204,010 | |
| FARALLON CAPITAL MANAGEMENT LLC | 0.46% | 43,225 | 0% | 0% | $185,868 |
| UBS Group AG | 0.38% | 35,555 | -27% | 0% | $152,887 |
| GOLDMAN SACHS GROUP INC | 0.35% | 33,131 | +38% | 0% | $142,463 |
| BANK OF AMERICA CORP /DE/ | 0.27% | 25,382 | +65% | 0% | $109,142 |
| Quadrature Capital Ltd | 0.22% | 20,964 | 0% | $90,145 | |
| Bank of New York Mellon Corp | 0.19% | 18,146 | +88% | 0% | $78,027 |
| Russell Investments Group, Ltd. | 0.17% | 15,966 | +1351% | 0% | $68,654 |
| XTX Topco Ltd | 0.14% | 12,838 | 0% | $55,203 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.12% | 11,802 | -23% | 0% | $50,749 |
| HRT FINANCIAL LP | 0.12% | 11,050 | 0% | $47,000 | |
| TWO SIGMA INVESTMENTS, LP | 0.11% | 10,492 | 0% | $45,116 | |
| Arax Advisory Partners | 0.09% | 8,400 | +277% | 0% | $36,120 |